A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis

Main Article Content

Adelaide Hebert
Debbie Glaab
Rhonda Schreiber

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Mayne Pharma.